How India Exports Carmustine to the World

In the United States, carmustine is approved under multiple Abbreviated New Drug Applications (ANDAs), indicating the presence of generic versions in the market. The FDA's Orange Book lists several approved ANDAs for carmustine, reflecting its established use in oncology. As of March 2026, there are no active import alerts related to carmustine, suggesting compliance with FDA regulations. The regulatory pathway for carmustine involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug, and adherence to Current Good Manufacturing Practices (CGMP). Given that 7.9% of India's carmustine exports are directed to the U.S., it is imperative for Indian exporters to maintain stringent quality standards to ensure market access.

In the European Union, carmustine has been granted marketing authorization as a generic medicine. For instance, Carmustine medac received approval from the European Medicines Agency (EMA) on July 18, 2018. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of carmustine products within the UK. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers, ensuring product quality and safety. With the United Kingdom accounting for 58.1% of India's carmustine exports, adherence to these regulatory standards is crucial for market retention.

Carmustine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in cancer treatment. It is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), which set the quality standards for pharmaceutical substances. These inclusions facilitate international trade and acceptance of carmustine, provided that manufacturers comply with the specified standards.

In India, carmustine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug requiring medical supervision. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, carmustine is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring that domestic supply is not adversely affected by international trade.

The primary patents for carmustine have expired, leading to the availability of generic versions and increased competition in the market. This generic competition has contributed to the widespread availability and affordability of carmustine globally.

In February 2026, the UK's MHRA issued a Class 2 Medicines Recall for a batch of Carmustine 100 mg Powder and Solvent for Concentrate for Solution for Infusion, due to an out-of-specification test result. (gov.uk) This recall highlights the critical importance of stringent quality control measures for manufacturers and exporters.

Additionally, in March 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for a new generic version of carmustine, indicating ongoing developments and approvals within the European market. These regulatory activities underscore the dynamic nature of the pharmaceutical landscape and the necessity for continuous compliance with evolving standards.

Carmustine, an alkylating agent used in chemotherapy, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to risks associated with geopolitical tensions and trade restrictions. For instance, in October 2025, the U.S. Pharmacopeia reported that nearly 41% of KSMs used in U.S.-approved APIs are sole-sourced from China, highlighting a significant vulnerability in the pharmaceutical supply chain.

Recent disruptions have further exacerbated these risks. In March 2026, the closure of the Strait of Hormuz following military conflicts led to significant delays in the shipment of chemical feedstocks, including those essential for API production. This disruption has caused procurement delays and forced some facilities to reduce output or declare force majeure.

Our proprietary trade data indicates a high supplier concentration in Carmustine exports from India. The top five exporters account for 93.1% of the total export value, with EMCURE PHARMACEUTICALS LIMITED alone contributing 76.1%. Such concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could disrupt the entire supply chain.

To mitigate this risk, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM production. This initiative seeks to reduce dependency on imports and diversify the supplier base. However, the effectiveness of the PLI scheme in addressing the specific vulnerabilities associated with Carmustine's supply chain remains to be fully realized. (pharmanow.live)

The recent escalation of conflicts in the Middle East has led to the effective closure of the Strait of Hormuz, a critical chokepoint for global shipping. This disruption has significantly impacted the transportation of chemical feedstocks essential for API production. As of March 2026, major carriers have suspended transits through the Strait due to security and insurance risks, leading to procurement delays and production cutbacks in the chemical industry.

Additionally, the U.S. Food and Drug Administration (FDA) has been monitoring supply chain disruptions that could affect the availability of critical medications. While no specific shortage alerts for Carmustine have been issued as of March 2026, the agency continues to assess the situation closely.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Strengthen Domestic Production: Leverage government initiatives like the PLI scheme to enhance local manufacturing capabilities for APIs and KSMs.

• Enhance Supply Chain Visibility: Implement advanced tracking systems to monitor the movement of raw materials and finished products, allowing for proactive responses to disruptions.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical tensions and shipping disruptions.

• Collaborate with Regulatory Bodies: Maintain open communication with agencies like the FDA to stay informed about potential shortages and regulatory changes.

RISK_LEVEL: HIGH